Peroxisome proliferator-activated receptor-γ protects against vascular aging

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 302, Issue 10, 2012, Pages

  Modrick, Mary L ^a   Kinzenbaw, Dale A ^a   Chu, Yi ^a   Sigmund, Curt D ^a   Faraci, Frank M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cardiovascular risk factors; Endothelium; Nitric oxide; Oxidative stress

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ENDOTHELIN 1; MESSENGER RNA; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SCAVENGER; SUPEROXIDE;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; C57BL 6 MOUSE; CARDIOVASCULAR FUNCTION; CAROTID ARTERY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AGING; ANIMALS; AORTA; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; GENE KNOCK-IN TECHNIQUES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, ANIMAL; NITROPRUSSIDE; OXIDATIVE STRESS; PPAR GAMMA; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84861158340     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00557.2011     Document Type: Article

References (49)

1. Al-Shali KZ, House AA, Hanley AJG, Khan HMR, Harris SB, Zinman B, Mamakeesick M, Fenster A, Spence JD, Hegele RA. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke 35: 2036-2040, 2004.
2. Argmann C, Dobrin R, Heikkinen S, Auburtin A, Pouilly L, Cock TA, Koutnikova H, Zhu J, Schadt EE, Auwerx J. Pparγ2 is a key driver of longevity in the mouse. PLOS Genet 5: e1000752, 2009.
3. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883, 1999.
4. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin. Hypertension 30: 817-824, 1997.
5. Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM. Interference with PPARγ signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51: 867-871, 2008.
6. dw/dwJ) mice. Aging Cell 3: 282-296, 2004.
7. Brown KA, Didion SP, Andresen JJ, Faraci FM. Effect of aging, MnSOD deficiency, and genetic background on endothelial function: Evidence for MnSOD haploinsufficiency. Arterioscler Thromb Vasc Biol 27: 1941-1946, 2007.
8. Chan SL, Cipolla MJ. Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferatoractivated receptor-γ. FASEB J 25: 3229-3239, 2011.
9. Chang K, Francis SA, Aikawa E, Figueiredo JL, Kohler RH, Mc-Carthy JR, Weissleder R, Plutzky J, Jaffer FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis. Novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol 30: 1933-1939, 2010.
10. Chu Y, Heistad DD, Knudtson KL, Lamping KG, Faraci FM. Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction. Arterioscler Thromb Vasc Biol 22: 611-616, 2002.
11. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPARγ activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 41: 1266-1270, 2010.
12. Cipolla MJ, Sweet JG, Chan SL. Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia. J Appl Physiol 110: 329-339, 2011.
13. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117: 2123-2130, 2008.
14. Didion SP, Kinzenbaw DA, Schrader LI, Faraci FM. Heterozygous CuZn superoxide dismutase deficiency produces a vascular phenotype with aging. Hypertension 48: 1072-1079, 2006.
15. Durrant JR, Seals DR, Connell ML, Russell MJ, Lawson BR, Folian BJ, Donato AJ, Lesniewski LA. Voluntary wheel running restores endothelial function in conduit arteries of old mice: Direct evidence for reduced oxidative stress, increased superoxide dismutase activity and down-regulation of NADPH oxidase. J Physiol 587: 3271-3285, 2009.
16. Faraci FM. Cerebral vascular dysfunction with aging. In: Handbook of the Biology of Aging, 7th ed., edited by Masoro EJ and Austad SN. New York: Academic, 2011, chap.19, pp. 405-418.
17. Faraci FM. Protecting against vascular disease in brain. The Robert M. Berne Distinguished Lecture. Am J Physiol Heart Circ Physiol 300: H1566-H1582, 2011.
18. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 24: 1367-1373, 2004.
19. Faraci FM, Sigmund CD, Shesely EG, Maeda N, Heistad DD. Responses of carotid artery in mice deficient in expression of the gene for endothelial NO synthase. Am J Physiol Heart Circ Physiol 274: H564-H570, 1998.
20. Fleenor BS, Seals DR, Zigler ML, Sindler AL. Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice. Aging Cell 11: 269-276, 2012.
21. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPARγ in smooth muscle causes vascular dysfunction and hypertension. Cell Metab 7: 215-226, 2008.
22. Harman D. Origin and evolution of the free radical theory of aging: a brief personal history, 1954-2009. Biogerontology 10: 773-781, 2009.
23. Homma S, Hirose N, Ishida H, Ishii T, Araki G. Carotid plaque and intima-media thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke 32: 830-835, 2001.
24. phox message expressions in primary endothelial cells. Metabolism 50: 3-11, 2001.
25. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging: Clinical vascular disease in the elderly. Circulation 123: 1900-1910, 2011.
26. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor-γ protect from hypertension directly through effects in the vasculature? J Biol Chem 285: 9311-9316, 2010.
27. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An anti-diabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ. J Biol Chem 270: 12953-12956, 1995.
28. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115: 459-467, 2007.
29. Marchesi C, Schiffrin EL. Peroxisome proliferator-activated receptors and the vascular system: beyond their metabolic effects. J Am Soc Hypertens 2: 227-238, 2008.
30. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551, 1999.
31. Mayhan WG, Arrick DM, Sharpe GM, Sun H. Age-related alterations in reactivity of cerebral arterioles: Role of oxidative stress. Microcirculation 15: 225-236, 2008.
32. Modrick ML, Didion SP, Sigmund CD, Faraci FM. Role of oxidative stress and AT1 receptors in cerebral vascular dysfunction with aging. Am J Physiol Heart Circ Physiol 296: H1914-H1919, 2009.
33. Najjar SS, Scuteri A, Lakatta Arterial aging EG. Is it an immutable cardiovascular risk factor? Hypertension 46: 454-462, 2005.
34. Nicolakakis N, Aboulkassim T, Ongali B, Lecrux C, Fernandes P, Rosa-Neto P, Tong XK, Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor γ agonist. J Neurosci 28: 9287-9296, 2008.
35. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 340: 14-22, 1999.
36. Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 27: 1908-1918, 2007.
37. Peraza M, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activator receptors. Toxicol Sci 90: 269-295, 2006.
38. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 451: 904-913, 2008.
39. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, Persidsky Y. Activation of peroxisome proliferator-activated receptor-γ suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 180: 1854-1865, 2008.
40. Roszer T, Ricote M. PPARs in the renal regulation of systemic blood pressure. PPAR Res 2010: 698730.
41. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. The PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43: 661-666, 2004.
42. Schmidt MV, Bernhard B, Von Knethen A. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases. Scientific World J 10: 2181-2197, 2010.
43. Seals DR, Jablokski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci 120: 357-375, 2011.
44. Shipley RD, Muller-Delp JM. Aging decreases vasoconstrictor responses of coronary resistance arterioles through endothelium-dependent mechanisms. Cardiovasc Res 66: 374-383, 2005.
45. Sung B, Park S, Yu BP, Chung HY. Modulation of PPAR in aging, inflammation, and calorie restriction. J Gerontol Series A: Biol Sci Med Sci 59: 997-1006, 2004.
46. Tsai YS, Kim HJ, Takahashi N, Kim HS, Hagaman JR, Kim JK, Maeda N. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J Clin Invest 114: 240-249, 2004.
47. 2+ mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104: 228-235, 2009.
48. Wray DW, Nishiyama SK, Harris RA, Zhao J, McDaniel J, Fjeldstad AS, Witman MAH, Ives SJ, Barrett-O'Keefe Z, Richardson RS. Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption. Hypertension In press.
49. Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB. The PPARγ agonist pioglitazone ameliorates aging-related progressive renal injury. J Am Soc Nephrol 20: 2380-2388, 2009.